Associated Papers
Rare variant genetic landscape of familial chylomicronemia syndrome (FCS) in the United Kingdom.
Bashir B et al.
Genetics in Medicine Open, 2025
Genetic variation in apolipoprotein A-V in hypertriglyceridemia.
Perera SD et al.
Current Opinion in Lipidology, 2024
Six years' experience with LipidSeq: clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias.
Dron JS et al.
Bmc Medical Genomics, 2020
Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes.
D'Erasmo L et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2019
Whole Exome Sequencing of HIV-1 long-term non-progressors identifies rare variants in genes encoding innate immune sensors and signaling molecules.
Nissen SK et al.
Scientific Reports, 2018
Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk.
Zhou Y et al.
Journal of Lipid Research, 2018
Polygenic determinants in extremes of high-density lipoprotein cholesterol.
Dron JS et al.
Journal of Lipid Research, 2017
Apolipoprotein A5 fifteen years anniversary: Lessons from genetic epidemiology.
Hubacek JA
Gene, 2016
Whole Exome Sequencing in Monogenic Dyslipidemias.
Tada H et al.
Journal of Atherosclerosis and Thrombosis, 2015
Structural and functional analysis of APOA5 mutations identified in patients with severe hypertriglyceridemia.
Mendoza-Barberá E et al.
Journal of Lipid Research, 2013
Resequencing the apolipoprotein A5 (APOA5) gene in patients with various forms of hypertriglyceridemia.
Evans D et al.
Atherosclerosis, 2011
The relative importance of common and rare genetic variants in the development of hypertriglyceridemia.
Evans D et al.
Expert Review of Cardiovascular Therapy, 2011
[Impact of apolipoprotein A5 on cardiovascular risk. Genetic and environmental modulation].
Sotos-Prieto M et al.
Revista Medica De Chile, 2010
Apolipoprotein A5 in health and disease.
Hubáček JA et al.
Physiological Research, 2009
Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding.
Dorfmeister B et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2008
APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels.
Hubacek JA et al.
Clinical Chemistry and Laboratory Medicine, 2008
Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650).
Wang J et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2007
Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels.
Pennacchio LA et al.
Human Molecular Genetics, 2002
Clinical and biochemical features of different molecular etiologies of familial chylomicronemia.
Hegele RA et al.
Journal of Clinical Lipidology, 0
Differential effects of volanesorsen on apoC-III, triglycerides, and pancreatitis in familial chylomicronemia syndrome diagnosed by genetic or nongenetic criteria.
Tsimikas S et al.
Journal of Clinical Lipidology, 0